ALPINE GROUP PARTNERS, LLC.
Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Biopharma company developing treatments for rare and ultra-rare diseases.
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)